Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunomodulation and blood transfusion.

Morris A Blajchman1

  • 1Department of Pathology, McMaster University, and Canadian Blood Services, Hamilton, Ontario, Canada. blajchma@mcmaster.ca

American Journal of Therapeutics
|September 19, 2002
PubMed
Summary

Allogeneic blood transfusions may cause transfusion-associated immunomodulation (TRIM), impacting transplant outcomes and potentially increasing infection risks. Further research is needed to confirm TRIM

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Age of transfused blood in critically ill adults.

The New England journal of medicine·2015
Same author

Effects of red-cell storage duration on patients undergoing cardiac surgery.

The New England journal of medicine·2015
Same author

Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial.

JAMA·2012
Same author

Addressing the risk of bacterial contamination of platelets within the United States: a history to help illuminate the future.

Transfusion·2012
Same author

The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop.

Transfusion·2012
Same author

Clinical review: Canadian National Advisory Committee on Blood and Blood Products--Massive transfusion consensus conference 2011: report of the panel.

Critical care (London, England)·2011

Area of Science:

  • Transfusion Medicine
  • Immunology
  • Transplantation

Background:

  • Evidence suggests allogeneic blood transfusions can cause immunosuppression.
  • This phenomenon, known as transfusion-associated immunomodulation (TRIM), is linked to renal transplant outcomes.
  • Potential adverse effects include increased cancer recurrence and bacterial infections.

Purpose of the Study:

  • To review the current understanding of TRIM.
  • To discuss the potential benefits and risks associated with TRIM.
  • To highlight the need for further research into TRIM's mechanisms and clinical relevance.

Main Methods:

  • Review of existing clinical data and experimental animal studies on TRIM.
  • Analysis of the association between TRIM and clinical outcomes.
  • Discussion of potential mechanisms and the role of leukoreduction.

Main Results:

  • TRIM has been associated with improved outcomes in renal transplantation.
  • TRIM may also increase the risk of cancer recurrence and postoperative infections.
  • Animal models suggest TRIM is leukocyte-mediated and can be reduced by leukoreduction.

Conclusions:

  • The precise mechanisms of TRIM remain unclear.
  • The clinical significance of TRIM, particularly regarding cancer and infection risks, requires further investigation.
  • More research is needed to fully understand and manage TRIM's effects.

Related Experiment Videos